Lung EpiCheck Biomarkers Development Study
- Conditions
- Lung Cancer
- Registration Number
- NCT06245876
- Lead Sponsor
- Nucleix Ltd.
- Brief Summary
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
- Detailed Description
This is a prospective, multi-center, observational nonsignificant risk study aimed to collect blood and clinical data from primary lung cancer and control subjects to characterize various biomarkers that will discriminate between lung cancer and control subjects.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 6000
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Performance Day 1 Performance of the assay in terms of (1) Sensitivity (2) Specificity (3) NPV (negative predictive value) and (4) PPV (positive predictive value).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (10)
Life Spring Clinical Research
🇺🇸Miami, Florida, United States
Emerald Coast OBGYN
🇺🇸Panama City, Florida, United States
Ochsner LSU Health Shreveport - Regional Urology
🇺🇸Shreveport, Louisiana, United States
Comprehensive Urology
🇺🇸Southfield, Michigan, United States
Michigan Institute of Urology, P.C.
🇺🇸Troy, Michigan, United States
Urology San Antonio
🇺🇸San Antonio, Texas, United States
National Koranyi Institute for Pulmonology
🇭🇺Budapest, Hungary
Carmel Medical Center
🇮🇱Haifa, Israel
Sourasky Medical Center
🇮🇱Tel Aviv, Israel
ZGT Medical Center
🇳🇱Hengelo, Netherlands
Life Spring Clinical Research🇺🇸Miami, Florida, United States